Comments from CEO:

The second quarter of our financial year (January–March 2025) has been one of fundamental transition, marked by external pressures and internal restructuring. This quarter has been focused on correcting the course and preparing for a more sustainable commercial model.

Despite the heavy internal focus, a delisting and supply challenges in Q2, we closed the quarter with a revenue of DKK 1.3 million (DKK 2,45 million), and an order intake of DKK 2.7 million, including DKK 1.8 million in recurring sales—all currently in production and with DKK 0,4 million in prepayments from customers. A revised commercial focus marks the beginning of a more predictable cash flow.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

About CS MEDICA A/S
Founded in 2011, CS MEDICA is a Danish MedTech company specializing in CBD-infused treatments for autoimmune and stress-related conditions, including arthritis, psoriasis, and pain management. Operating at the intersection of the pharmaceutical and cosmetics industries, CS MEDICA delivers clinically supported products with fewer side effects, offering competitive and accessible alternatives. With MDR-approved products, cutting-edge R&D, and the benefits of CBD, the company provides innovative, safe, and effective solutions. Its capital-light business model and trusted European production partners further enhance its ability to offer high-quality treatments, setting CS MEDICA apart in the MedTech sector.